Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist, who heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg, brings extensive expertise in spectroscopy and materials research that will be instrumental in advancing the company's scientific endeavors.
Prof. Rubhausen's research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry. He utilizes these techniques to study superconductors, quantum materials, and biological samples at large-scale research facilities such as PETRA III and FLASH. His interdisciplinary work has resulted in over 180 publications with approximately 4,000 citations, including contributions to leading scientific journals like Physical Review Letters, Nature Physics, and Angewandte Chemie. Additionally, he is developing AI-supported analysis workflows for complex datasets, a skill set that could prove valuable in analyzing the effects of cold plasma on various materials.
The appointment is part of Viromed's strategy to deepen its research capabilities. Uwe Perbandt, CEO of Viromed Medical AG, commented, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the development, manufacture, and distribution of medical products. Its operating business, Viromed Medical GmbH, distributes innovative cold plasma technology for medical applications, primarily in the DACH region. The company aims to further advance the use of cold plasma in medicine and capitalize on its growth potential. By adding Prof. Rubhausen to its advisory board, Viromed is reinforcing its commitment to scientific excellence and innovation.
Prof. Rubhausen's appointment underscores the importance of understanding the interaction between cold plasma and biological materials. Cold plasma, which is ionized gas at near-room temperature, has shown promise in medical applications such as wound healing and disinfection. However, the mechanisms underlying its effects are not fully understood. Prof. Rubhausen's expertise in spectroscopy could help elucidate these mechanisms, potentially leading to more effective and targeted treatments.
The Medical Advisory Board of Viromed now benefits from Prof. Rubhausen's deep knowledge of materials research and his experience with cutting-edge analytical techniques. His insights may guide the company's research toward new applications and improved product efficacy. As Viromed continues to expand its portfolio, the collaboration with Prof. Rubhausen is expected to drive innovation and maintain the company's pioneering role in cold plasma technology.
For more information about Viromed Medical AG, visit their website at www.viromed-medical-ag.de. The original press release is available on NewMediaWire.
